Refractec's ViewPoint

Phase III clinical trial of the "laserless" conductive keratoplasty device for presbyopia gains FDA go-ahead. System uses radio frequency energy to shrink collagen tissue within the cornea, thus reshaping it and eliminating the need for reading glasses, firm explains. FDA also has accepted a final module of the Irvine, California firm's PMA for hyperopia treatment